全球现症乙型肝炎病毒(HBV)感染者约3．5亿, 每年有50-100万患者死于HBV感染相关疾病。慢性乙型肝炎(CHB)随着病情的进展而发生肝硬化和肝癌已是不争的事实,严重威胁人们的健康。近年,乙型肝炎抗病毒药物的研究进展较大,为临床医师提供了较多抗病毒治疗的选择;因而美国、欧洲、亚太地区及我国相继修订了乙型肝炎的防治指南,为临床医师的临床诊断治疗工作提供参考。 Worldwide, about 350 million people are infected with hepatitis B virus, and 500,000 to 1,000,000 people die each year from HBV-related diseases. Chronic hepatitis B (CHB) With the progress of the disease and cirrhosis and liver cancer has become an indisputable fact that a serious threat to people’s health. In recent years, research on hepatitis B antiviral drugs has made great progress, providing clinicians with more options for antiviral therapy. Therefore, the United States, Europe, the Asia Pacific region and China have successively revised the guidelines for the prevention and treatment of hepatitis B for clinicians Clinical diagnosis and treatment to provide reference.